Historical wst News Stories
WST Stock: GLP-1 Demand Fuels Q4 Beat; Shares Slip
West Pharmaceutical beat Q4 expectations driven by GLP‑1 injectable demand, but the stock showed short-term volatility and remains below its 52‑week peak. Strong financials, improving technicals and high-margin product mix underpin the outlook, while investors watch for sustained price strength.
WST Strategic Pivot: Synchrony S1, SmartDose Exit.
West Pharmaceutical (WST) has accelerated a strategic shift: launching the Synchrony™ S1 prefilled syringe system while agreeing to sell its SmartDose® 3.5 mL on‑body injector business to AbbVie. Recent moves aim to concentrate resources on high‑value injectable solutions even as the stock lags peers.
WST Falls 2.29% on Broad Selloff; Volume Jumps Now
West Pharmaceutical Services (WST) dropped 2.29% on Feb 5, 2026, amid a broader market decline. Trading volume spiked to ~1.2M shares — well above the 50-day average — while no company-specific news surfaced. This article breaks down the move, peer behavior, and what investors should monitor next.